Constantijn van Rietschoten appointed Executive Board member for International Markets
|
EQS-News: Medios AG
/ Key word(s): Personnel
Medios AG: Constantijn van Rietschoten appointed Executive Board member for International Markets
Berlin, May 6, 2024 – The Supervisory Board of Medios AG ("Medios") has appointed Constantijn van Rietschoten as member to the Company's Executive Board with effect from May 1, 2024. In his new role as Chief International Markets, van Rietschoten, who had previously been Head of International Business Development at Medios since April 2023, will assume responsibility for the entire international business and its further development. He has been appointed for a three year term, expiring on April 30, 2027. Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: "The European Specialty Pharma market offers great potential. We are therefore very pleased to welcome Constantijn van Rietschoten as Executive Board Member for International Markets. His outstanding expertise and international experience will be of great value for Medios’ international growth ambitions, which are now also reflected in the internationalization of the Company's Executive Board. We wish him every success in his new role." Constantijn van Rietschoten, Executive Board Member at Medios AG: "Medios is a highly interesting company with a rapid development – recently also beyond the German borders following the acquisition of the Dutch market leader Ceban. I am delighted to contribute to the further internationalization of Medios and the development of a leading European Specialty Pharma platform.“ Prior to joining Medios in April 2023, van Rietschoten worked for Fagron for over 14 years. As member of the Executive Leadership Team, he held positions of Chief Marketing Officer, Chief Corporate Affairs Officer, and most recently as Area Leader EMEA. Van Rietschoten studied Public Administration at Erasmus University Rotterdam (the Netherlands). Important dates for Medios AG in the 2024 financial year May 7: Quarterly statement as at March 31, 2024 June 6 to 7: Warburg Highlights – Hamburg August 13: Half-Year-Financial Report 2024 August 14: Annual General Meeting 2024 September 25: Berenberg and Goldman Sachs 13th German Corporate Conference – Munich November 12: Quarterly statement as of September 30, 2024 ------------------- About Medios AG Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies. Medios AG is Germany's first listed specialty pharmaceutical company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). www.medios.ag Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Medios AG Heidestraße 9 | 10557 Berlin T +49 30 232 566 800 c.nickolaus@medios.ag www.medios.ag Disclaimer This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing.
06.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 - 800 |
| Fax: | +49 30 232 566 - 801 |
| E-mail: | ir@medios.ag |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1896455 |
| End of News | EQS News Service |
|
|
1896455 06.05.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.